Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, underscoring the need for more effective, comprehensive treatments.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Jaina Patel was in her early 30s when a bout of bronchitis led to hear losing weight, her job and eventually her sense of smell - until a clinical trial worked wonders ...

Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively increasing symptom burden, exercise limitations, and frequent ...

Whilebiological drugs or biologics have improved the lives of many people with severe asthma, a new study shows that some ...

Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from baseline through 16 weeks with APG777, an anti-IL-13 antibody from Apogee ...

Head-to-Head Trial Finds Winner for CRSwNP With Asthma Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to ...